Same-day CAR-T production is established and refined through the comparison of novel vector and gene-editing strategies with classical methods. Both processes are then standardized to ensure consistent, clinical-scale use. It develops cutting-edge analytical assays - leveraging CRISPR off-target profiling, 3D ex vivo efficacy screens, and cytokine-release monitoring - to qualify edited cells for safety and potency. Finally, it conducts paired comparisons of the new rapid workflow versus traditional ex vivo culture to demonstrate equivalence or superiority in product quality.
Ulf is a co‑founder and CEO of T‑CURX, with more than 20 years of experience in founding, building, and successfully exiting biotechnology companies. Prior to T‑CURX, he co‑founded 4‑Antibody AG and NBE‑Therapeutics, both of which were acquired by international pharma companies, and led the companies as CEO through significant venture financings and major commercial transactions. Ulf holds a PhD in Biochemistry and has an extensive background in immunology, with over 40 peer‑reviewed publications and multiple granted and pending patents.
Jan van den Brulle serves as VP External Research & Development at T‑CURX and brings more than 20 years of experience in research and development across multiple biotechnology companies. Prior to joining T‑CURX, he held senior leadership roles at MorphoSys AG and Sloning Biotechnology, where he led large research teams, managed global pharma collaborations, and advanced multiple therapeutic antibody programs to lead candidate stage. Jan has a strong background in synthetic biology and is an inventor on numerous granted patents in the field.
Paulina serves as Director Business Development & Program Management at T‑CURX, where she leads the clinical CAR‑T pipeline program TCX‑001 and drives partnering and fundraising activities. She brings more than 15 years of experience across Medical Affairs, business strategy, and CAR‑T research, including her previous role as Medical Director Cellular Therapies at Bristol Myers Squibb, where she supported the commercialization of CAR‑T therapies in lymphoma and multiple myeloma. Paulina holds a PhD in tumor immunology with a focus on CAR‑T research.
